BIOCYTOGEN
Biocytogen is a clinical stage biopharmaceutical company that integrates proprietary gene editing technology, transgenic mouse platforms to generate fully human antibodies, comprehensive animal models and high-throughput in vivo antibody discovery. We have established fully integrated research and development capabilities ranging from early target discovery to clinical development. Our focus on research and development and technological innovation serves as the cornerstone of our continuing growth. We intend to develop and commercialize first-in-class or best-in-class drugs to contribute to the improvement of human health worldwide.
BIOCYTOGEN
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2008-11-01
Status:
Active
Contact:
781-587-3558
Total Funding:
335.15 M USD
Technology used in webpage:
Domain Not Resolving IPv6 Person Schema Google Google Cloud Cloudflare Hosting Facebook Sharer Gravatar Profiles SiteXpress
Similar Organizations
SyMap Medical
SyMap Medical is an innovative medical device company.
Current Employees Featured
Yuelei Shen President & CEO @ Biocytogen
President & CEO
2008-06-01
Tianquan Jin Vice President @ Biocytogen
Vice President
2011-11-01
Chaoshe Guo Vice President Sales and Marketing @ Biocytogen
Vice President Sales and Marketing
2016-04-01
Founder
Stock Details
Investors List
Remegen
Remegen investment in Post-IPO Equity - Biocytogen
Veken Technology
Veken Technology investment in Post-IPO Equity - Biocytogen
OrbiMed
OrbiMed investment in Series E - Biocytogen
CPE
CPE investment in Series E - Biocytogen
Octagon Capital Partners
Octagon Capital Partners investment in Series E - Biocytogen
Lake Bleu Capital
Lake Bleu Capital investment in Series E - Biocytogen
CMB International Capital Corporation
CMB International Capital Corporation investment in Series D - Biocytogen
China Life Healthcare Fund
China Life Healthcare Fund investment in Series D - Biocytogen
Cowin Capital
Cowin Capital investment in Series D - Biocytogen
3E Bioventures
3E Bioventures investment in Series D - Biocytogen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-02 | Doma Biopharmaceutical | Biocytogen investment in Series A - Doma Biopharmaceutical | 950 M CNY |
More informations about "Biocytogen"
About the Company | Biocytogen
Biocytogen Biocytogen provides one-stop solutions for next-generation drug development, supporting the global biomedical community from target identification to IND application. Leveraging proprietary gene-editing technology and the innovative RenMice ® platforms, …See details»
Preclinical CRO, Animal Models & Human Antibodies
Based on this innovative technique, Biocytogen employs a large-fragment in situ replacement strategy to seamlessly substitute human antibody gene sequences while preserving the mouse Fc region. This ensures the production of fully …See details»
Biocytogen - The Org
Biocytogen is a preclinical stage biotech that provides a one-stop solution for antibody discovery from target to IND application. With cutting-edge technologies, state-of-art animal facility, and …See details»
Biocytogen - LinkedIn
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the ...See details»
Biocytogen - Crunchbase Investor Profile & Investments
Biocytogen works with the world's leading pharmaceutical and biotechnology companies. Read More. Lists Featuring This Company. Edit Lists Featuring …See details»
Biocytogen Completes a New Round of Financing …
Jun 22, 2021 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was established in 2009. ... With the implementation of these platforms, Biocytogen has evolved from a contract research organization (CRO) into an ...See details»
Chinese Biotech Firm Biocytogen Bags Tens of Millions …
Jun 22, 2021 Established in 2008, Biocytogen is a comprehensive contract research organization (CRO), providing one-stop R&D services for preclinical research of biopharmaceuticals. At present, Biocytogen has R&D and service …See details»
Biocytogen Pharmaceuticals (Beijing) | BioPharm America
Company/Organization Description or Summary . Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotech company that drives the research and development of new drugs with …See details»
Join BIOCYTOGEN at AACR-NCI-EORTC INTERNATIONAL …
Join Biocytogen at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 from April 27-30 in Chicago. Explore groundbreaking cancer …See details»
Biocytogen Expands Global Reach with New San Diego Office
Beijing, Boston, MA, and San Diego, CA, March 17, 2025 — Biocytogen (“Biocytogen,” HKEX: 02315), a global biotech company advancing antibody-based drug discovery with innovative …See details»
Biocytogen - Products, Competitors, Financials, Employees, …
Biocytogen operates as a preclinical contract research organization (CRO) in the biomedical sector, focusing on antibody drug development. The company provides services such as gene …See details»
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. - BIO International ...
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Biocytogen …See details»
Biocytogen - Funding, Financials, Valuation & Investors - Crunchbase
Biocytogen is registered under the ticker HKG:02315 . Their stock opened with HK$25.22 in its Sep 1, 2022 IPO. Stock Symbol HKG:02315 ; Valuation at IPO $357M; Money Raised at IPO …See details»
Biocytogen Information - RocketReach
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a …See details»
Envigo announces collaboration with Biocytogen to distribute the …
Sep 28, 2021 As the largest organization that is solely dedicated to providing research models and related products and services, we are committed to helping researchers realize the full …See details»
Cell Lines | Biocytogen
Biocytogen, with over a decade of engineering experience, has successfully modified a variety of cell lines. The company integrates gene editing technologies such as EGE, ES, and has …See details»
Biocytogen Announces the Merger of Eucure Biopharma to Create …
Biocytogen has established a unique one-stop development system covering the whole drug development process by organically integrating the single-cell antibody discovery technology …See details»
Biocytogen, LLC - Massachusetts Biomedical Initiatives
Biocytogen is a leader in providing humanized mouse models to evaluate the efficacy of human immunotherapies. The company has continued to grow and raise a total of over $335M. …See details»
SOTIO Enters into Multi-Target Antibody Agreement with …
Jul 16, 2024 Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million; SOTIO Biotech, a clinical-stage biopharmaceutical …See details»
Biocytogen, Radiance partner for bispecific antibody-drug conjugate
Jan 9, 2024 Biocytogen Pharmaceuticals and Radiance Biopharma have signed an exclusive option and licence agreement for a bispecific antibody-drug conjugate (BsADC). The …See details»